InspireMD, Inc. (NSPR) · Nov 20, 2026 · Share issuance
$5.3M over-allotment — Additional net proceeds of ~$5.3M; total offering net proceeds of ~$40.2M
InspireMD’s offering closes with an extra $5.3M from the full over-allotment, extending funding for its TCAR launch but adding more dilution.
InspireMD is in a capital-funded commercialization transition: FDA approval has opened its CGuard Prime platform to U.S. TCAR procedures, while the company is rebuilding its CAS business after a delivery-system recall and preparing a potential relaunch in the first half of 2027. Its immediate commercial focus is the U.S. TCAR launch, with the first commercial procedures already announced; third-quarter international revenue was only $2.2 million.
The financing closed as expected, adding liquidity but not changing the story. The underwriter exercised the full over-allotment, and the closing produced approximately $5.3 million of additional net proceeds. The option exercise had already been disclosed on November 18, and the offering documents had indicated approximately $40.2 million of net proceeds if the option was exercised in full, so this filing confirms an anticipated outcome rather than delivering a new financing surprise.
| Initial offering | Full offering | |
|---|---|---|
| Net proceeds (Offering) | $34.9M | ~$40.2M |
| Additional net proceeds (Over-allotment) | — | ~$5.3M |
The cash supports the launch phase, but it is equity-funded runway. The proceeds give InspireMD more resources for sales, marketing, research and development, and working capital as it commercializes TCAR and advances the CAS relaunch. But the funding comes alongside additional shares and warrants, so it increases the capital base without proving that the new U.S. indication will generate meaningful revenue. The filing therefore improves near-term execution capacity while leaving the central commercialization risk unchanged.
Bottom line: This is a useful liquidity extension, not a strategic reset. Because the over-allotment was already announced and exercised before the filing, its business impact is largely confirmation rather than fresh upside.
U.S. TCAR commercial ramp; CAS PMA supplement expected December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!